These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

679 related articles for article (PubMed ID: 19358611)

  • 1. Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.
    Bezençon O; Bur D; Weller T; Richard-Bildstein S; Remen L; Sifferlen T; Corminboeuf O; Grisostomi C; Boss C; Prade L; Delahaye S; Treiber A; Strickner P; Binkert C; Hess P; Steiner B; Fischli W
    J Med Chem; 2009 Jun; 52(12):3689-702. PubMed ID: 19358611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.
    Scheiper B; Matter H; Steinhagen H; Böcskei Z; Fleury V; McCort G
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5480-6. PubMed ID: 21840218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors.
    Scheiper B; Matter H; Steinhagen H; Stilz U; Böcskei Z; Fleury V; McCort G
    Bioorg Med Chem Lett; 2010 Nov; 20(21):6268-72. PubMed ID: 20850300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of orally bioavailable alkyl amine renin inhibitors.
    Xu Z; Cacatian S; Yuan J; Simpson RD; Jia L; Zhao W; Tice CM; Flaherty PT; Guo J; Ishchenko A; Singh SB; Wu Z; McKeever BM; Scott BB; Bukhtiyarov Y; Berbaum J; Mason J; Panemangalore R; Cappiello MG; Bentley R; Doe CP; Harrison RK; McGeehan GM; Dillard LW; Baldwin JJ; Claremon DA
    Bioorg Med Chem Lett; 2010 Jan; 20(2):694-9. PubMed ID: 19959358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds.
    Matter H; Scheiper B; Steinhagen H; Böcskei Z; Fleury V; McCort G
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5487-92. PubMed ID: 21840215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 6-ethyl-2,4-diaminopyrimidine-based small molecule renin inhibitors.
    Holsworth DD; Jalaie M; Belliotti T; Cai C; Collard W; Ferreira S; Powell NA; Stier M; Zhang E; McConnell P; Mochalkin I; Ryan MJ; Bryant J; Li T; Kasani A; Subedi R; Maiti SN; Edmunds JJ
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3575-80. PubMed ID: 17482464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and optimization of new piperidines as renin inhibitors.
    Corminboeuf O; Bezençon O; Grisostomi C; Remeň L; Richard-Bildstein S; Bur D; Prade L; Hess P; Strickner P; Fischli W; Steiner B; Treiber A
    Bioorg Med Chem Lett; 2010 Nov; 20(21):6286-90. PubMed ID: 20843686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and initial SAR of arylsulfonylpiperazine inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1).
    Sun D; Wang Z; Di Y; Jaen JC; Labelle M; Ma J; Miao S; Sudom A; Tang L; Tomooka CS; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3513-6. PubMed ID: 18511278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors.
    Dublanchet AC; Ducrot P; Andrianjara C; O'Gara M; Morales R; Compère D; Denis A; Blais S; Cluzeau P; Courté K; Hamon J; Moreau F; Prunet ML; Tertre A
    Bioorg Med Chem Lett; 2005 Aug; 15(16):3787-90. PubMed ID: 16002291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
    Tice CM; Xu Z; Yuan J; Simpson RD; Cacatian ST; Flaherty PT; Zhao W; Guo J; Ishchenko A; Singh SB; Wu Z; Scott BB; Bukhtiyarov Y; Berbaum J; Mason J; Panemangalore R; Cappiello MG; Müller D; Harrison RK; McGeehan GM; Dillard LW; Baldwin JJ; Claremon DA
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3541-5. PubMed ID: 19457666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational design of new bifunctional inhibitors of type II dehydroquinase.
    Toscano MD; Stewart KA; Coggins JR; Lapthorn AJ; Abell C
    Org Biomol Chem; 2005 Sep; 3(17):3102-4. PubMed ID: 16106291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors.
    Andrews DM; Stokes ES; Carr GR; Matusiak ZS; Roberts CA; Waring MJ; Brady MC; Chresta CM; East SJ
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2580-4. PubMed ID: 18378449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors.
    Powell NA; Ciske FL; Cai C; Holsworth DD; Mennen K; Van Huis CA; Jalaie M; Day J; Mastronardi M; McConnell P; Mochalkin I; Zhang E; Ryan MJ; Bryant J; Collard W; Ferreira S; Gu C; Collins R; Edmunds JJ
    Bioorg Med Chem; 2007 Sep; 15(17):5912-49. PubMed ID: 17574423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, structure-activity relationships, X-ray crystal structure, and energetic contributions of a critical P1 pharmacophore: 3-chloroindole-7-yl-based factor Xa inhibitors.
    Shi Y; Sitkoff D; Zhang J; Klei HE; Kish K; Liu EC; Hartl KS; Seiler SM; Chang M; Huang C; Youssef S; Steinbacher TE; Schumacher WA; Grazier N; Pudzianowski A; Apedo A; Discenza L; Yanchunas J; Stein PD; Atwal KS
    J Med Chem; 2008 Dec; 51(23):7541-51. PubMed ID: 18998662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.
    Cogan DA; Aungst R; Breinlinger EC; Fadra T; Goldberg DR; Hao MH; Kroe R; Moss N; Pargellis C; Qian KC; Swinamer AD
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3251-5. PubMed ID: 18462940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.
    Nicolotti O; Catto M; Giangreco I; Barletta M; Leonetti F; Stefanachi A; Pisani L; Cellamare S; Tortorella P; Loiodice F; Carotti A
    Eur J Med Chem; 2012 Dec; 58():368-76. PubMed ID: 23149299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of piperidine farnesyltransferase inhibitors with reduced glucuronidation potential.
    Tanaka R; Rubio A; Harn NK; Gernert D; Grese TA; Eishima J; Hara M; Yoda N; Ohashi R; Kuwabara T; Soga S; Akinaga S; Nara S; Kanda Y
    Bioorg Med Chem; 2007 Feb; 15(3):1363-82. PubMed ID: 17127066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension.
    Chen A; Bayly C; Bezençon O; Richard-Bildstein S; Dubé D; Dubé L; Gagné S; Gallant M; Gaudreault M; Grimm E; Houle R; Lacombe P; Laliberté S; Lévesque JF; Liu S; MacDonald D; Mackay B; Martin D; McKay D; Powell D; Remen L; Soisson S; Toulmond S
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2204-9. PubMed ID: 20206513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
    Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
    J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines.
    Chen A; Campeau LC; Cauchon E; Chefson A; Ducharme Y; Dubé D; Falgueyret JP; Fournier PA; Gagné S; Grimm E; Han Y; Houle R; Huang JQ; Lacombe P; Laliberté S; Lévesque JF; Liu S; MacDonald D; Mackay B; McKay D; Percival MD; Regan C; Regan H; St-Jacques R; Toulmond S
    Bioorg Med Chem Lett; 2011 Jul; 21(13):3970-5. PubMed ID: 21621998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.